Literature DB >> 18971949

Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases.

P Chevallier, N Robillard, G Houille, S Ayari, T Guillaume, J Delaunay, J-L Harousseau, H Avet-Loiseau, M Mohty, R Garand.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18971949     DOI： 10.1038/leu.2008.303

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Characterization of CD22 expression in acute lymphoblastic leukemia.

Authors:  Nirali N Shah; Maryalice Stetler Stevenson; Constance M Yuan; Kelly Richards; Cindy Delbrook; Robert J Kreitman; Ira Pastan; Alan S Wayne
Journal:  Pediatr Blood Cancer       Date:  2015-03-01       Impact factor: 3.167

2.  Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.

Authors:  Patrice Chevallier; Francoise Huguet; Emmanuel Raffoux; Anne Etienne; Thibaut Leguay; Francoise Isnard; Nelly Robillard; Thierry Guillaume; Jacques Delaunay; Aude Charbonnier; Arnaud Pigneux; Pierre Peterlin; Marie C Bené; William A Wegener; David M Goldenberg; Hervé Dombret
Journal:  Haematologica       Date:  2014-12-31       Impact factor: 9.941

Review 3.  Mechanisms of resistance to CAR T cell therapy.

Authors:  Nirali N Shah; Terry J Fry
Journal:  Nat Rev Clin Oncol       Date:  2019-06       Impact factor: 66.675

4.  DNA methylation markers in the diagnosis and prognosis of common leukemias.

Authors:  Hua Jiang; Zhiying Ou; Yingyi He; Meixing Yu; Shaoqing Wu; Gen Li; Jie Zhu; Ru Zhang; Jiayi Wang; Lianghong Zheng; Xiaohong Zhang; Wenge Hao; Liya He; Xiaoqiong Gu; Qingli Quan; Edward Zhang; Huiyan Luo; Wei Wei; Zhihuan Li; Guangxi Zang; Charlotte Zhang; Tina Poon; Daniel Zhang; Ian Ziyar; Run-Ze Zhang; Oulan Li; Linhai Cheng; Taylor Shimizu; Xinping Cui; Jian-Kang Zhu; Xin Sun; Kang Zhang
Journal:  Signal Transduct Target Ther       Date:  2020-01-10

5.  Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.

Authors:  Sarwish Rafiq; Anthony Siadak; Jonathan P Butchar; Carolyn Cheney; Gerard Lozanski; Naduparambil K Jacob; Rosa Lapalombella; Jackie McGourty; Meghan Moledor; Richard Lowe; Ben Setter; Jeffrey Jones; Joseph M Flynn; Leslie Andritsos; Steven Devine; Xiaokui Mo; David Jarjoura; Susheela Tridandapani; Paul Algate; John C Byrd; Natarajan Muthusamy
Journal:  MAbs       Date:  2013-06-07       Impact factor: 5.857

6.  Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes.

Authors:  Peter Meyerhuber; Heinke Conrad; Lilian Stärck; Matthias Leisegang; Dirk H Busch; Wolfgang Uckert; Helga Bernhard
Journal:  J Mol Med (Berl)       Date:  2010-08-11       Impact factor: 4.599

7.  XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells.

Authors:  S Rafiq; C Cheney; X Mo; D Jarjoura; N Muthusamy; J C Byrd
Journal:  Leukemia       Date:  2012-02-15       Impact factor: 11.528

Review 8.  The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies.

Authors:  Victor D Fedorov; Vivek A Upadhyay; Amir T Fathi
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

Review 9.  Acute lymphoblastic leukemia: a comprehensive review and 2017 update.

Authors:  T Terwilliger; M Abdul-Hay
Journal:  Blood Cancer J       Date:  2017-06-30       Impact factor: 11.037

10.  Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab.

Authors:  Sebastian P Haen; Benjamin J Schmiedel; Kathrin Rothfelder; Bastian J Schmied; Truong-Minh Dang; Nora Mirza; Robert Möhle; Lothar Kanz; Wichard Vogel; Helmut R Salih
Journal:  Oncotarget       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.